CardioComm Solutions' Novel Wireless and WEB Based ECG Management Software will be the Heart of Wireless Arrhythmia Services in the USA
CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions"
or the "Company") today announced the limited release of its new
proprietary GEMS? Air software, electrocardiogram ("ECG") SDK viewer
(GUAVA?) and a new customized web-based device interface. The pre
GEMS? 4.0 version will be incorporated into wireless arrhythmia
services for the remote diagnostic arrhythmia and remote patient
The new GEMS? Air software solution was designed to simplify the work
flow associated with real-time, wireless cardiac monitoring. While
broad commercial release of GEMS? 4.0 is scheduled for later this
year, Philips Healthcare and TZ Medical have leveraged this limited
advanced version of the software, along with its customized web-based
device interface, in their remote diagnostic arrhythmia monitoring
technology and services. Both companies will each separately announce
their product debuts during the Heart Rhythm 2012 Annual Scientific
Sessions in Boston, MA.
"CardioComm Solutions is continuing to strengthen its alliances with
many Tier 1 health service leaders," said Dr. Anatoly Langer, Chairman
of CardioComm Solutions' Board. "Our ongoing work with international
medical technology companies is a critical part of this long term
strategy. This newest of our GEMS? based software technology advances
is already of significant interest to medical companies that possess
large global sales and marketing networks and that possess, or can
access, existing relationships with the world's cardiologists,
hospitals and monitoring services," Dr. Langer added.
"For the past three years CardioComm Solutions has been compiling new
GEMS? and GUAVA? solutions to enable the integration of multiple ECG
recording and transmitting devices that have received FDA market
clearance, Health Canada Medical Device Licensure, as well as the
European CE Mark for medical devices. This release marks another
important milestone in achieving that objective," noted Etienne Grima,
Chief Executive Officer of CardioComm Solutions. "CardioComm Solutions
continues to demonstrate that we are an innovative solutions provider
that meets the business and medical care challenges associated with
the growing ECG monitoring markets."
"CardioComm Solutions has developed the most advanced connectivity
option between device and medical call centre. Their GEMS? software is
the engine behind the launch of the AERA CT mobile Cardiac telemetry
(MCT) device and will be part of the international marketing efforts
of TZ Medical," stated John Lubisich, President, TZ Medical, Inc.
"CardioComm Solutions has worked with Philips as a preferred provider
of ECG interfaces and management tools for many years within the
cardiac monitoring service environment," said Martha Dolan, Marketing
Director, Philips Remote Cardiac Services. "With their logical
approach to solutions development and their on-time business delivery,
CardioComm Solutions has proven to be a reliable provider in support
of our goal to improve the lives of our patients."
The global Cardiovascular Monitoring and Diagnostic devices market is
forecast to reach US$12 billion by 2015 with the North American
segment accounting for approximately 40%, Europe more than 25% and
Asia-Pacific as the fastest growing region driving a value of US$3.4
billion. "These early start US based strategic relationships highlight
the opportunities that can be replicated in Canada, South America and
overseas by leveraging CardioComm Solutions' multi-country client
base," adds Mr. Grima.
About CardioComm Solutions
CardioComm Solution's patented and proprietary technology is used in
products for recording, viewing, analyzing and storing
electrocardiograms (ECGs) for diagnosis and management of cardiac
patients. Products are sold worldwide through a combination of an
external distribution network and a North American-based sales team.
The company has earned the ISO 13485 certification, is HPB approved,
HIPAA compliant, and has received FDA market clearance for its
software devices. CardioComm Solutions, Inc. is headquartered in
Toronto, Canada, with offices in Victoria, B.C.
This release may contain certain forward-looking statements with
respect to the financial condition, results of operations and business
of CardioComm Solutions and certain of the plans and objectives of
CardioComm Solutions with respect to these items. By their nature,
forward-looking statements involve risk and uncertainty because they
relate to events and depend on circumstances that will occur in the
future and there are many factors that could cause actual results and
developments to differ materially from those expressed or implied by
these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release